Nyxoah Achieves Key Clinical and Regulatory Milestones

(24/7 MARKET NEWS) – Nyxoah SA (Nasdaq: NYXH) reported, this morning, completing all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study.

Nyxoah is at $5.88, up $0.76 (+14.84%), on 110 thousand premarket shares.

Its 52-week trading range is $4.36 to $20.03. It’s challenging its 2023 highs and has a little resistance to the $10 level, but it needs a huge volume inflow to make such a move.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist